Previous 10 | Next 10 |
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diso...
Anavex Life Sciences Corp. ( NASDAQ: AVXL ), a biotech focused on central nervous system (CNS) diseases, announced Wednesday that the U.S. regulators granted the company a new patient covering its lead candidate ANAVEX 2-73. An oral therapy also known as blarcamesine, ANAVEX...
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental dis...
Summary Anavex has two big catalysts coming up, both in Alzheimer’s disease and Parkinson’s Disease Dementia. Results reported so far show long-lasting cognition changes, and I am expecting Anavex to report improvement in cognition of patients on the upcoming trial r...
Summary Treatments such as Aricept and likely simufilam that inhibit the formation of the nitro-oxidant peroxynitrite and speed its decomposition stabilize Alzheimer's disease for about a year. Treatments (blarcamesine, Trappsol Cyclo, panax ginseng) that inhibit the formation of ...
Mechanism of Action of ANAVEX ® 2-73 (blarcamesine) and ANAVEX ® 3-71 (AF710B) is the activation of SIGMAR1 Endogenous increase in SIGMAR1 activation as a compensatory mechanism against early Alzheimer's disease Top line results of randomized, placebo-c...
Recent research is claiming pivotal study data was falsified in order to bolster the amyloid hypothesis. This should have a positive impact on Alzheimer's programs based on other mechanisms. Anavex is one of them. A paper recently came out in Science magazine that ha...
Image source: The Motley Fool. Anavex Life Sciences (NASDAQ: AVXL) Q3 2022 Earnings Call Aug 09, 2022 , 4:30 p.m. ET Clint Tomlinson Continue reading For further details see: Anavex Life Sciences (AVXL) Q3 2022 Earnings Call Transcript
Anavex Life Sciences Corp. (AVXL) Q3 2022 Results Conference Call August 09, 2022 04:30 PM ET Company Participants Clint Tomlinson - IR Dr. Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants ...
Anavex Life Sciences press release ( NASDAQ: AVXL ): Q3 GAAP EPS of -$0.16 beats by $0.01 . Cash and cash equivalents of $153.2 million on June 30, 2022, compared to $152.1 million at fiscal year end September 30, 2021. For further details see: Anavex Life Sc...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...